Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993078 | 0.93 | MTNR1A (0.46) | NPC1RAB9ASMN1; SMN2ROCK1BRAF | |
| SCHEMBL4002272 | 0.83 | MEN1 (0.59) | NPC1RAB9ASMN1; SMN2BRAFMTNR1A | |
| SCHEMBL3998615 | 0.82 | MEN1 (0.58) | NPC1RAB9ASMN1; SMN2BRAFMTNR1A | |
| SCHEMBL3998610 | 0.81 | MEN1 (0.57) | NPC1RAB9ASMN1; SMN2BRAFMTNR1A | |
| SCHEMBL4008389 | 0.79 | ROCK1 (0.45) | ROCK1BRAFKDRCDK8 | |
| SCHEMBL4008675 | 0.77 | NR1H2 (0.47) | NPC1RAB9AROCK1 | |
| SCHEMBL3998754 | 0.77 | MEN1 (0.56) | SMN1; SMN2BRAFMTNR1AMTNR1BMEN1 | |
| SCHEMBL12888865 | 0.75 | MAPK1 (0.65) | NPC1RAB9ASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL3728925 | 0.74 | ALDH1A1 (0.56) | NPC1RAB9ASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL21697451 | 0.74 | EGFR (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547779-B2 | Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| EP-1675552-A4 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-25 | — | — | US | disclosed |
| EP-1675552-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037197-A2 | PREPERATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234261-A1 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors | TNK2, ROCK1, ARHGDIB | NPC1 4184/4885RAB9A 641/4885SMN1; SMN2 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.